Sorry, Tesaro. AZ's Lynparza won a broader-than-expected approval in ovarian cancer, putting it on even footing with Tesaro’s recent launch, Zejula.…

Eli Lilly’s RA med baricitinib had been pegged as one of 2017’s hottest launches—and a threat to Pfizer’s Xeljanz. Not anymore.

Opioid makers face a task that’s partly old, partly new. Besides training docs on their meds' risks, they'd have to include info on rival therapies.

Transparency hasn't made much of a difference when it comes to drug and device makers' payments to doctors, which amounted to $2.6 billion last year.

With biologics dominating its pipeline, Sanofi will spend as much as $2 billion on its biologics manufacturing network over the next several years.

Novo Nordisk just took another step toward a potential kick-start for its newest basal insulin, Tresiba.

In the immuno-oncology rivalry between Merck’s Keytruda and BMS’ Opdivo, Keytruda has been running the table. But Opdivo boasts the latest win.

California lawmakers are weighing a bill that would cut off most drugmaker payments to physicians, including speaking fees for that staple of pharma marketing…